Европейская академия естественных наук Hannover E.V.

Yuming Xu

Yuming Xu, M.D. Ph.D., is a Second-Level Professor, a Chief Physician in Neurology, Director of the Education and Research Department of Neurology in the First Affiliated Hospital of Zhengzhou University, a Fellow of the “Renowned Physicians of Central China”, the Director of the National Health Commission’s Key Laboratory for Prevention and Treatment of Cerebrovascular Diseases (Co-built), the Honorary Chairman of the High-Risk Cerebrovascular Disease Population Management Branch of the Chinese Stroke Association, and the President of the Henan Stroke Society. Dr. Xu has been the principal investigator for one National Key Research and Development Program Project and six National Natural Science Foundation of China (NSFC) grants, including one NSFC Key Project. He has authored more than 300 basic and clinical medical research papers in leading journals, including Lancet Neurology, Brain, and Annals of Neurology, achieving a total impact factor exceeding 1000 and an H-index of 42. Dr. Xu serves as the Editor-in-Chief or Co-Editor-in-Chief for more than 20 national guidelines and consensus on stroke prevention and treatment. Additionally, he has contributed to eight textbooks for higher education and monographs on neurology. He has been recognized with one first-class and three second-class Science and Technology Progress Awards from Henan Province, and he holds two national invention patents. Dr. Xu ranked 25th among the top 100 Academic Influential National Neurology Scholars from 2013 to 2022 and was elected to the global scholars’ database.

Dr. Xu established a comprehensive stroke prevention and control model known as "Prevention-Treatment-Management-Rehabilitation" in Henan Province, He played a pivotal role in establishing 104 county-level stroke prevention and treatment centers and over 400 stroke centers, promoting the adoption of advanced therapeutic technologies such as intravenous thrombolysis, mechanical thrombectomy, and carotid endarterectomy. His efforts have resulted in over 50,000 annual cases of intravenous thrombolysis, greatly reducing the mortality and disability rates of stroke patients in Henan. Dr. Xu established a community high-risk population cohort of 1.12 million people and explored the mechanisms of occurrence and outcomes of stroke and implementing interventions. He was the first to identify STUB1 as a novel causative gene for Gordon-Holmes syndrome and investigated its pathological mechanisms and diagnostic applications. He also identified and characterized new gene mutations and dysfunctions associated with neurodegenerative diseases, including PRRT2、APP、PS1、GARS、IGHMBP2、CCM1、SPG11、MMAACH、PLA2G6、CHCHD2、RAB39B and WISP3. Dr. Xu pioneered the use of skin neurovascular micro-biopsy technique, established reference value range for IENFD in the Chinese population, and discovered phosphorylated-α-synuclein deposits in the dermal nerves of synucleinopathy patients, providing a reliable biomarker for the diagnosis of Parkinson's diseases and other synucleinopathies. He developed multiple diagnostic and disease assessment models for neuronal intranuclear inclusion diseases (NIID). Dr. Xu initiated jointly the world’s first clinical trial using transplantation of human embryonic stem cells-derived neural precursor cells for the treatment of Parkinson`s Disease, offering new therapeutic options. He also conducted clinical trials of nerve growth factor (NGF) for the treatment for spinocerebellar ataxia (SCA), providing a new treatment for this condition. Dr. Xu established an iPS cell bank generated from patients with well-defined genetic backgrounds in Henan Province, laying the foundation for mechanistic studies and drug screening for neurogenetic degenerative diseases. Throughout his career, Dr. Xu has mentored more than 200 master’s and doctoral students, making a lasting contribution to the future of the neurology field.

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт